{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:18:07Z","timestamp":1789777087270,"version":"4.0.1"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016348","name":"Kyowa Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease (ESKD), but currently available treatments do not improve kidney function or prevent the initiation of dialysis\/kidney replacement therapy. A previous study demonstrated that bardoxolone methyl improves the estimated glomerular filtration rate (eGFR), but the study was prematurely terminated because of an imbalance in heart failure between treatment groups. The subsequent phase 2 TSUBAKI study demonstrated no incidence of heart failure and an improved eGFR and GFR as determined by inulin clearance in DKD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This randomized, double-blind, placebo-controlled multicentre phase 3 study was designed to assess the efficacy and safety of bardoxolone methyl in DKD patients with an eGFR \u226515.0\u2013&amp;lt;60.0\u00a0ml\/min\/1.73\u00a0m2 and a urinary albumin:creatinine ratio (UACR) \u22643500\u00a0mg\/g but without risk factors for heart failure. The primary endpoint is the time to onset of a \u226530% decrease in the eGFR or ESKD. Randomized patients (1:1) have been under treatment with once-daily oral bardoxolone methyl (5, 10 or 15\u00a0mg by intrapatient dose adjustment) or placebo for at least 3\u00a0years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean age of the 1013 patients is 65.9\u00a0years, 21.5% are female, the mean eGFR is 37.84\u00a0ml\/min\/1.73\u00a0m2 and the median UACR is 351.80\u00a0mg\/g.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Appropriate patients are enrolled in this study. This study will investigate the long-term efficacy and safety of bardoxolone methyl in DKD patients covering a wider range of eGFR (\u226515.0\u2013&amp;lt;60.0\u00a0ml\/min\/1.73\u00a0m2) and albuminuria (\u22643500\u00a0mg\/g) compared with previous studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfac242","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T09:33:01Z","timestamp":1661333581000},"page":"1204-1216","source":"Crossref","is-referenced-by-count":49,"title":["Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study"],"prefix":"10.1093","volume":"38","author":[{"given":"Masaomi","family":"Nangaku","sequence":"first","affiliation":[{"name":"Division of Nephrology and Endocrinology, the University of Tokyo Graduate School of Medicine , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Takama","sequence":"additional","affiliation":[{"name":"Research & Development Division, Kyowa Kirin , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Ichikawa","sequence":"additional","affiliation":[{"name":"Research & Development Division, Kyowa Kirin , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Mukai","sequence":"additional","affiliation":[{"name":"Research & Development Division, Kyowa Kirin , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kojima","sequence":"additional","affiliation":[{"name":"Research & Development Division, Kyowa Kirin , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Juntendo University Faculty of Medicine , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5961-1816","authenticated-orcid":false,"given":"Hirotaka","family":"Watada","sequence":"additional","affiliation":[{"name":"Department of Metabolism and Endocrinology, Juntendo University Graduate School of Medicine , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0123-3645","authenticated-orcid":false,"given":"Takashi","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Laboratory Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University , Ishikawa , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohjiro","family":"Ueki","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology, and Metabolism, Center Hospital, National Center for Global Health and Medicine , Tokyo, Japan"},{"name":"Department of Molecular Diabetic Medicine, Diabetes Research Center, Research Institute, National Center for Global Health and Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiei","family":"Narita","sequence":"additional","affiliation":[{"name":"Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences , Niigata , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kashihara","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, Kawasaki Medical School , Okayama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kadowaki","sequence":"additional","affiliation":[{"name":"Toranomon Hospital , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Hase","sequence":"additional","affiliation":[{"name":"Aoba Hospital , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Akizawa","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Showa University School of Medicine , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"issue":"Suppl 1","key":"2023050410464879600_bib1","first-page":"S79","article-title":"Nephropathy in diabetes","volume":"27","author":"Molitch","year":"2004","journal-title":"Diabetes Care"},{"key":"2023050410464879600_bib2","first-page":"S1","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98(4 Suppl)","author":"Kidney Disease: Improving Global Outcomes Diabetes Work Group","year":"2020","journal-title":"Kidney Int"},{"key":"2023050410464879600_bib3","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2023050410464879600_bib4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.ajkd.2009.05.011","article-title":"Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial","volume":"54","author":"Akizawa","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"2023050410464879600_bib5","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","article-title":"The pathobiology of diabetic complications: a unifying mechanism","volume":"54","author":"Brownlee","year":"2005","journal-title":"Diabetes"},{"key":"2023050410464879600_bib6","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1073\/pnas.0500815102","article-title":"Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress","volume":"102","author":"Dinkova-Kostova","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023050410464879600_bib7","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.2337\/db06-0147","article-title":"Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic Leprdb\/bd mice","volume":"55","author":"Szab\u00f3","year":"2006","journal-title":"Diabetes"},{"key":"2023050410464879600_bib8","doi-asserted-by":"crossref","first-page":"460","DOI":"10.2337\/db07-1119","article-title":"Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway","volume":"57","author":"Thallas-Bonke","year":"2008","journal-title":"Diabetes"},{"key":"2023050410464879600_bib9","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/1535-7163.MCT-06-0516","article-title":"Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes","volume":"6","author":"Yates","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"2023050410464879600_bib10","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1021\/np100826q","article-title":"New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress","volume":"74","author":"Sporn","year":"2011","journal-title":"J Nat Prod"},{"key":"2023050410464879600_bib11","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/ki.2012.439","article-title":"Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease","volume":"83","author":"Ruiz","year":"2013","journal-title":"Kidney Int"},{"key":"2023050410464879600_bib12","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1152\/physrev.00023.2017","article-title":"The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis","volume":"98","author":"Yamamoto","year":"2018","journal-title":"Physiol Rev"},{"key":"2023050410464879600_bib13","article-title":"Ministry project team to lead the world in the practical application of innovative medical products","author":"Ministry of Health, Labour and Welfare","year":"2018"},{"key":"2023050410464879600_bib14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1105351","article-title":"Bardoxolone methyl and kidney function in CKD with type 2 diabetes","volume":"365","author":"Pergola","year":"2011","journal-title":"N Engl J Med"},{"key":"2023050410464879600_bib15","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"de Zeeuw","year":"2013","journal-title":"N Engl J Med"},{"key":"2023050410464879600_bib16","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ekir.2020.03.030","article-title":"Randomized clinical trial on the effect of bardoxolone methyl on GFR in diabetic kidney disease patients (TSUBAKI study)","volume":"5","author":"Nangaku","year":"2020","journal-title":"Kidney Int Rep"},{"key":"2023050410464879600_bib17","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.cardfail.2014.10.001","article-title":"Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl","volume":"20","author":"Chin","year":"2014","journal-title":"J Card Fail"},{"key":"2023050410464879600_bib18","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.kint.2017.04.019","article-title":"Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference","volume":"92","author":"Baigent","year":"2017","journal-title":"Kidney Int"},{"key":"2023050410464879600_bib19","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1007\/s10157-018-1615-x","article-title":"Guidelines for clinical evaluation of chronic kidney disease: AMED research on regulatory science of pharmaceuticals and medical devices","volume":"22","author":"Kanda","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"2023050410464879600_bib20","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"2023050410464879600_bib21","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1007\/s10157-019-01730-9","article-title":"Analysis of 2897 hospitalization events for patients with chronic kidney disease: results from CKD-JAC study","volume":"23","author":"Iimuro","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"2023050410464879600_bib22","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2023050410464879600_bib23","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1159\/000484633","article-title":"The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics","volume":"46","author":"Jardine","year":"2017","journal-title":"Am J Nephrol"},{"key":"2023050410464879600_bib24","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/dom.13245","article-title":"Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: a clinical trial design novel to diabetic nephropathy","volume":"20","author":"Heerspink","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2023050410464879600_bib25","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1111\/dom.13315","article-title":"Baseline characteristics and enrichment results from the SONAR trial","volume":"20","author":"Heerspink","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2023050410464879600_bib26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000503713","article-title":"Design and baseline characteristics of the Finerenone in reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease trial","volume":"50","author":"Bakris","year":"2019","journal-title":"Am J Nephrol"},{"key":"2023050410464879600_bib27","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/ndt\/gfz290","article-title":"Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial","volume":"35","author":"Heerspink","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2023050410464879600_bib28","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/ndt\/gfaa234","article-title":"The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) trial: baseline characteristics","volume":"35","author":"Wheeler","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2023050410464879600_bib29","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes CKD Work Group","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"2023050410464879600_bib30","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10157-020-01881-0","article-title":"Nonproteinuric diabetic kidney disease","volume":"24","author":"Yamanouchi","year":"2020","journal-title":"Clin Exp Nephrol"},{"key":"2023050410464879600_bib31","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1001\/jama.289.24.3273","article-title":"Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus","volume":"289","author":"Kramer","year":"2003","journal-title":"JAMA"},{"key":"2023050410464879600_bib32","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.2337\/dc09-1098","article-title":"Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study","volume":"33","author":"Molitch","year":"2010","journal-title":"Diabetes Care"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfac242\/46052450\/gfac242.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/38\/5\/1204\/50195017\/gfac242.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/38\/5\/1204\/50195017\/gfac242.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T07:33:48Z","timestamp":1683185628000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/38\/5\/1204\/6674775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,8,24]]},"published-print":{"date-parts":[[2023,5,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfac242","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5]]},"published":{"date-parts":[[2022,8,24]]}}}